Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the United States… In vitro studies have demonstrated the ability of Sigyn Therapy to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma… Sigyn designed the ImmunePrep platform to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody. The company believes its reverse decoy mechanism will increase the availability of antibodies to interact with their intended disease targets, and, simultaneously, the devices will also extract disease targets from the bloodstream to further improve patient benefits,” a recent article explains. “Recent scientific publications have reported that only 1% of chemotherapy is delivered to the tumor cell targets of cancer patients. In response, the Sigyn team designed ChemoPrep to overcome a delivery limitation of the most commonly administered drug to treat cancer. The company is developing ChemoPrep to reduce the circulating presence of tumor-derived exosomes (tumor exosomes), which interfere with chemotherapy delivery… Inversely, the Sigyn team recognized that if 99% of chemotherapy was missing its target, then there was a need to eliminate off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage. This factor led to the design of ChemoPure to reduce treatment toxicity by reducing the presence of off-target chemotherapy from the bloodstream.”
To view the full article, visit https://ibn.fm/w3hqj
About Sigyn Therapeutics Inc.
Sigyn Therapeutics is a development-stage, medical-technology company headquartered in San Diego, California. The company’s therapeutic candidates include the ImmunePrep(TM) platform, ChemoPrep(TM), ChemoPure(TM) and Sigyn Therapy(TM). For more information, visit the company’s website at www.SigynTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN